Nymox Pharmaceutical Corporation
OTCPK:NYMX.F 株式レポート
Nymox Pharmaceutical マネジメント Nymox Pharmaceuticalの CEO はPaul Averbackで、 Sep1995年に任命され、 の在任期間は 29.17年です。 は、会社の株式の37.43%を直接所有しており、その価値は$ 1.75M 。経営陣と取締役会の平均在任期間はそれぞれ6.3年と13.9年です。
主要情報 CEO給与比率 n/a CEO在任期間 29.2yrs CEOの所有権 37.4% 経営陣の平均在職期間 6.3yrs 取締役会の平均在任期間 13.9yrs
経営陣の近況
Nymox Pharmaceutical Corporation Appoints Patrick Doody as Vice President, General Counsel and Member of Board of Directors Jul 13
Nymox Pharmaceutical Corporation, Annual General Meeting, Dec 12, 2022 Nov 17
Insufficient new directors Nov 16
Nymox Pharmaceutical Corporation, Annual General Meeting, Dec 12, 2022 Nov 15
Nymox Pharmaceutical Corporation Announces Resignation of Erik Danielsen as Chief Financial Officer Jul 09
Insufficient new directors Apr 27
すべての更新を表示 Nymox Pharmaceutical Corporation Reports Victory in Bahamas Litigation Against Terminated Ex-Employees – Court Awards Costs and Damages Mar 27
Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH Sep 26
The Nasdaq Stock Market to Delist the Common Stock of Nymox Pharmaceutical Sep 08 Nymox Pharmaceutical Corporation announced that it expects to receive $2 million in funding Aug 03
Nymox Pharmaceutical Corporation Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results Jul 26
Nymox Pharmaceutical Corporation Appoints Patrick Doody as Vice President, General Counsel and Member of Board of Directors Jul 13
Nymox Delisting from NASDAQ Jul 06
New major risk - Share price stability Jul 01
Nymox Pharmaceutical Corporation Announces New Marketing Submission for Nymozarfex for BPH Dec 06
Nymox Pharmaceutical Corporation, Annual General Meeting, Dec 12, 2022 Nov 17
Insufficient new directors Nov 16
Nymox Pharmaceutical Corporation, Annual General Meeting, Dec 12, 2022 Nov 15
Nymox gets FDA feedback on NDA resubmission for lead asset Sep 13
Is Nymox Pharmaceutical (NASDAQ:NYMX) In A Good Position To Deliver On Growth Plans? Aug 17
NYMOX Receives Deficiency Letter from NASDAQ Jul 15
NYMOX stock down 7.2% after receiving non-compliance letter from Nasdaq Jul 14
Nymox Pharmaceutical Corporation Announces Resignation of Erik Danielsen as Chief Financial Officer Jul 09
NYMOX Receives RTF letter from FDA May 24
Insufficient new directors Apr 27
Nymox Pharmaceutical Corporation Announces Submission of New Drug Application to the FDA for Fexapotide Triflutate Mar 05 Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000E Value Index
Nymox to file for Fexapotide approval by mid-September May 06
Nymox Pharmaceutical Corporation announced that it expects to receive $7.999998 million in funding Apr 29
Independent Director recently bought US$83k worth of stock Apr 28
Nymox under pressure on $8M private placement Apr 28
Full year 2020 earnings released: US$0.16 loss per share (vs US$0.19 loss in FY 2019) Mar 31
What You Need To Know About Nymox Pharmaceutical Corporation's (NASDAQ:NYMX) Investor Composition Mar 01
New 90-day high: US$3.10 Feb 11
New 90-day high: US$2.83 Dec 19
New 90-day low: US$1.84 Dec 02
Nymox Pharmaceutical Corporation, Annual General Meeting, Dec 21, 2020 Nov 21
New 90-day low: US$2.07 Oct 28
New 90-day low: US$2.20 Oct 10
New 90-day low: US$2.37 Sep 18
New 90-day low - US$2.55 Aug 29
Nymox Pharmaceutical Corporation has completed a Follow-on Equity Offering in the amount of $9 million. Aug 17
First half earnings released Aug 16
New 90-day low - US$2.75 Aug 12
CEO報酬分析 Nymox Pharmaceutical の収益と比較して、Paul Averback の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Dec 31 2023 US$157k n/a -US$9m
Sep 30 2023 n/a n/a -US$5m
Jun 30 2023 n/a n/a -US$5m
Mar 31 2023 n/a n/a -US$3m
Dec 31 2022 US$747k n/a -US$7m
Sep 30 2022 n/a n/a -US$8m
Jun 30 2022 n/a n/a -US$10m
Mar 31 2022 n/a n/a -US$15m
Dec 31 2021 US$1m n/a -US$13m
Sep 30 2021 n/a n/a -US$12m
Jun 30 2021 n/a n/a -US$13m
Mar 31 2021 n/a n/a -US$12m
Dec 31 2020 US$1m n/a -US$12m
Sep 30 2020 n/a n/a -US$12m
Jun 30 2020 n/a n/a -US$11m
Mar 31 2020 n/a n/a -US$13m
Dec 31 2019 US$2m n/a -US$13m
Sep 30 2019 n/a n/a -US$13m
Jun 30 2019 n/a n/a -US$14m
Mar 31 2019 n/a n/a -US$11m
Dec 31 2018 US$2m US$600k -US$11m
Sep 30 2018 n/a n/a -US$11m
Jun 30 2018 n/a n/a -US$13m
Mar 31 2018 n/a n/a -US$13m
Dec 31 2017 US$5m US$5m -US$13m
報酬と市場: Paulの 総報酬 ($USD 157.00K ) は、 US市場 ($USD 648.89K ) の同様の規模の企業の平均を下回っています。
報酬と収益: Paulの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者 Dr. Paul Averback, M.D., D A.B.P., has been the President of Nymox Pharmaceutical Corporation since September 1995 and serves as its Chief Executive Officer. Dr. Averback is the Founder of Nymox Pharmaceut ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Founder 29.2yrs US$157.00k 37.43% $ 1.8m QA and Compliance Manager 6.3yrs データなし データなし VP, General Counsel & Director 1.3yrs US$32.87k データなし
もっと見る
経験豊富な経営陣: NYMX.Fの経営陣は経験豊富で 経験豊富 です（平均在職期間は6.3年）。
取締役 名称 ポジション 在職期間 報酬 所有権 Founder 29.2yrs US$157.00k 37.43% $ 1.8m VP, General Counsel & Director 1.3yrs US$32.87k データなし Independent Director 18.4yrs データなし 0.00042% $ 19.6 Independent Director 9.3yrs データなし 7.16% $ 335.1k
もっと見る
経験豊富なボード: NYMX.Fの 取締役会 は経験豊富で 経験豊富 です ( 13.9年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
